Less Ads, More Data, More Tools Register for FREE

Pin to quick picksERGO.L Regulatory News (ERGO)

  • There is currently no data for ERGO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Results of 2023 Annual General Meeting

22 Jun 2023 12:47

RNS Number : 6228D
Ergomed plc
22 June 2023
 

 

Results of 2023 Annual General Meeting

 

Guildford, 22 June 2023: Ergomed plc (AIM: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces the results of voting on the resolutions put to shareholders at its Annual General Meeting held earlier today. All resolutions were duly passed.

 

Details of the voting by way of a poll at the AGM in respect of each resolution are shown in the table below:

 

Resolution number

Resolution

Votes for

Votes against

Abstentions

1

Accounts

39,697,194

912,240

81,986

2

Reappoint auditor

40,736,227

1,255

80

3

Reappoint Anne Whitaker

40,269,559

457,733

337

4

Reappoint Jonathan Curtain

40,607,611

129,614

337

5

Reappoint Llew Keltner

39,853,733

827,308

446

6

Allot securities

38,791,006

1,946,219

337

7

Pre-emption rights

38,049,052

2,498,173

190,337

8

Pre-emption rights (acquisition)

38,061,085

2,676,140

337

 

 

The full text of all resolutions can be found in the Notice of Annual General Meeting on the Company's website www.ergomedplc.com.

 

 

ENDS

 

Enquiries:

 

Ergomed plc

 Tel: +44 (0) 1483 402 975

Miroslav Reljanović (Executive Chairman)

Jonathan Curtain (Chief Financial Officer)

Keith Byrne (Senior Vice President, Capital Markets and Strategy)

 

 

Numis Securities Limited (Nominated Adviser and Joint Broker)

Tel: +44 (0) 20 7260 1000

Freddie Barnfield / Euan Brown / Jack McLaren

 

Peel Hunt Securities Limited (Joint Broker)

James Steel / Dr Christopher Golden

 

 

Tel: +44 (0) 20 7418 8900

 

Consilium Strategic Communications -for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Matthew Neal

ergomed@consilium-comms.com

 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand. For further information, visit: http://ergomedplc.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGFTMBTMTITBIJ
Date   Source Headline
4th Apr 20227:00 amRNSIssue of Consideration Shares
1st Apr 202211:25 amRNSTotal Voting Rights
29th Mar 20227:00 amRNSErgomed Preliminary Results 2021
9th Mar 20227:00 amRNSJohn Dawson CBE Appointed to Ergomed Board as NED
1st Mar 20227:00 amRNSTotal Voting Rights
28th Feb 20227:00 amRNSErgomed Notice of Preliminary Results
11th Feb 20224:06 pmRNSDirector's Dealing
9th Feb 20227:00 amRNSAcquisition of ADAMAS
2nd Feb 20225:47 pmRNSHolding(s) in Company
25th Jan 20227:00 amRNSErgomed 2021 Trading Update
4th Jan 20227:00 amRNSTotal Voting Rights and Block Listing Return
1st Dec 20217:00 amRNSTotal Voting Rights
25th Nov 20217:00 amRNSExercise of Options
23rd Nov 20211:10 pmRNSHoldings in Company
15th Nov 20217:00 amRNSErgomed to Present at Jefferies Conference 2021
1st Nov 20217:00 amRNSTotal Voting Rights
25th Oct 20217:00 amRNSExercise of Share Options and Total Voting Rights
21st Oct 202110:20 amRNSHolding(s) in Company
5th Oct 20217:10 amEQSErgomed (ERGO): US is now the biggest market in the mix
5th Oct 20217:01 amEQSCreo Medical (CREO): Initiation - Providing energy for endoscopic surgery
1st Oct 20217:00 amRNSTotal Voting Rights
28th Sep 20217:00 amRNSErgomed Interim results
1st Sep 20217:00 amRNSTotal Voting Rights
23rd Aug 20217:00 amRNSNotice of Interim Results
19th Aug 202112:06 pmRNSHolding(s) in Company
18th Aug 202112:24 pmRNSHolding(s) in Company
18th Aug 202112:09 pmRNSDirector dealings
12th Aug 20217:01 amEQSErgomed (ERGO): Momentum continues with EBITDA upgrades
2nd Aug 20217:00 amRNSTotal Voting Rights
27th Jul 20217:00 amRNSTrading Update
19th Jul 20217:00 amRNSAppointment of Joint Corporate Broker
1st Jul 20217:00 amRNSBlock listing Interim Review
1st Jul 20217:00 amRNSTotal Voting Rights
17th Jun 20214:28 pmRNSHolding(s) in Company
17th Jun 20217:05 amRNSBoard Change
14th Jun 20218:14 amEQSErgomed (ERGO): FY21e EBITDA 'materially ahead' of consensus
10th Jun 202110:00 amRNSResult of AGM
10th Jun 20217:00 amRNSAGM Statement
2nd Jun 20218:00 amEQSEdison Investment Research Limited: Ergomed (ERGO): What's next after stellar 2020 performance?
1st Jun 20217:00 amRNSTotal Voting Rights
28th May 20217:00 amRNSErgomed to Present at Jefferies Conference
14th May 202111:30 amRNSHolding(s) in Company
14th May 20217:00 amRNSNotice of AGM and Annual Report
10th May 20217:00 amRNSBoard Changes
4th May 20217:00 amRNSTotal Voting Rights
29th Apr 20214:35 pmRNSPrice Monitoring Extension
29th Apr 20217:00 amRNSBoard Changes
26th Apr 20217:00 amRNSErgomed expands operations in Japan
1st Apr 20217:00 amRNSTotal Voting Rights
23rd Mar 20217:00 amRNSAudited Full Year Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.